B P Rubin

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans
    Brian P Rubin
    Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    J Clin Oncol 20:3586-91. 2002
  2. ncbi A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E
    Brian P Rubin
    Department of Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Cancer Res 65:6631-9. 2005
  3. ncbi Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors
    Brian P Rubin
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Lab Invest 86:981-6. 2006
  4. ncbi Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors
    Brian P Rubin
    Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Arch Pathol Lab Med 130:1616-29. 2006
  5. ncbi Gastrointestinal stromal tumours: an update
    B P Rubin
    Department of Anatomic Pathology, University of Washington Medical Center, 1959 NE Pacific Street, Box 356100, Seattle, WA 98195, USA
    Histopathology 48:83-96. 2006
  6. ncbi Isochromosome 7q in adult Wilms' tumors: diagnostic and pathogenetic implications
    B P Rubin
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Surg Pathol 24:1663-9. 2000
  7. ncbi Recent progress in the classification of soft tissue tumors: role of genetics and clinical implications
    B P Rubin
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Curr Opin Oncol 13:256-60. 2001
  8. ncbi KIT mutations in GIST
    Jonathan A Fletcher
    Brigham and Women s Hospital, 75 Francis Street, Thorn 5, Boston, MA 02115, USA
    Curr Opin Genet Dev 17:3-7. 2007
  9. ncbi An unusual case of Erdheim-Chester disease with features of Langerhans cell histiocytosis
    Paul S Furmanczyk
    Department of Pathology, University of Washington Medical Center, 1959 NE Pacific, P O Box 356100, Seattle, WA 98195 6100, USA
    Skeletal Radiol 36:885-9. 2007
  10. ncbi Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall
    Maggie M Lam
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Int J Gynecol Pathol 25:288-92. 2006

Detail Information

Publications52

  1. ncbi Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans
    Brian P Rubin
    Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    J Clin Oncol 20:3586-91. 2002
    ..We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate...
  2. ncbi A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E
    Brian P Rubin
    Department of Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Cancer Res 65:6631-9. 2005
    ....
  3. ncbi Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors
    Brian P Rubin
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Lab Invest 86:981-6. 2006
    ..This paper focuses on what is known about mechanisms of resistance in the treatment of solid tumors by small molecule kinase inhibitors...
  4. ncbi Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors
    Brian P Rubin
    Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Arch Pathol Lab Med 130:1616-29. 2006
  5. ncbi Gastrointestinal stromal tumours: an update
    B P Rubin
    Department of Anatomic Pathology, University of Washington Medical Center, 1959 NE Pacific Street, Box 356100, Seattle, WA 98195, USA
    Histopathology 48:83-96. 2006
    ..It is the purpose of this review to summarize recent developments in GIST classification and the molecular pathogenesis of GIST...
  6. ncbi Isochromosome 7q in adult Wilms' tumors: diagnostic and pathogenetic implications
    B P Rubin
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Surg Pathol 24:1663-9. 2000
    ..These genetic features may be helpful in distinguishing adult Wilms' tumors from other primary renal tumors...
  7. ncbi Recent progress in the classification of soft tissue tumors: role of genetics and clinical implications
    B P Rubin
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Curr Opin Oncol 13:256-60. 2001
    ..These examples illustrate the type of progress that is being made in the classification of soft tissue tumors...
  8. ncbi KIT mutations in GIST
    Jonathan A Fletcher
    Brigham and Women s Hospital, 75 Francis Street, Thorn 5, Boston, MA 02115, USA
    Curr Opin Genet Dev 17:3-7. 2007
    ..Alternately, the mutant kinase proteins can be targeted using HSP90 inhibitors, which result in degradation of activated KIT and/or PDGFRA, or using KIT transcriptional repressors, such as flavopiridol...
  9. ncbi An unusual case of Erdheim-Chester disease with features of Langerhans cell histiocytosis
    Paul S Furmanczyk
    Department of Pathology, University of Washington Medical Center, 1959 NE Pacific, P O Box 356100, Seattle, WA 98195 6100, USA
    Skeletal Radiol 36:885-9. 2007
    ..The clinical/radiologic and pathologic features that distinguish ECD and LCH as distinct entities are reviewed, and the underlying biological connection between them is discussed...
  10. ncbi Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall
    Maggie M Lam
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Int J Gynecol Pathol 25:288-92. 2006
    ..Thus, it is imperative to consider EGISTs in the differential diagnosis of mesenchymal neoplasms in the vulvovaginal/rectovaginal septum...
  11. ncbi Tissue response and Msx1 expression after human fetal digit tip amputation in vitro
    Christopher H Allan
    Department of Orthopaedics and Sports Medicine, University of Washington School of Medicine Harborview Medical Center, Seattle, Washington 98104, USA
    Wound Repair Regen 14:398-404. 2006
    ..This process appears spatially associated with Msx1 expression. Msx1 expression appears increased at the regrowing tip of 57-day digits by 4 days after amputation...
  12. ncbi Cytologic diagnosis of gastrointestinal stromal tumor with emphasis on the differential diagnosis with leiomyosarcoma
    T J Wieczorek
    Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Cancer 93:276-87. 2001
    ....
  13. ncbi Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Christopher D M Fletcher
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston MA 02115, USA
    Hum Pathol 33:459-65. 2002
    ....
  14. ncbi Diagnosis of gastrointestinal stromal tumors: a consensus approach
    Christopher D M Fletcher
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston MA 02115, USA
    Int J Surg Pathol 10:81-9. 2002
    ....
  15. ncbi Gastrointestinal stromal tumour
    Brian P Rubin
    Department of Anatomic Pathology, Taussig Cancer Center and the Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Lancet 369:1731-41. 2007
    ..The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours...
  16. ncbi The genetics of lipomatous tumors
    B P Rubin
    Department of Pathology, University of Washington Medical Center, Seattle, USA
    Semin Diagn Pathol 18:286-93. 2001
    ..The review describes characteristic cytogenetic and molecular genetic profiles and discusses their significance. The clinicopathologic features of these tumors, which are described elsewhere, will not be included in this review...
  17. pmc Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma
    N F Esnaola
    Division of Surgical Oncology, Department of Surgery, Radiation Oncology and Pathology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Surg 234:215-23. 2001
    ..Future systemic therapies should be targeted to patients with localized/locoregional disease and partial responders to conventional chemotherapy...
  18. pmc Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling
    A H Beck
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Oncogene 29:845-54. 2010
    ..04). In this analysis that combined gene expression profiling, aCGH and IHC, we characterized distinct molecular LMS subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers...
  19. ncbi Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer
    B P Rubin
    Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Eur J Cancer Prev 10:77-82. 2001
    ....
  20. ncbi KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
    B P Rubin
    Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 61:8118-21. 2001
    ..These studies underscore the role of KIT activation in GIST pathogenesis, and they suggest that activated KIT might represent a universal therapeutic target in GISTs...
  21. ncbi The gene expression profile of extraskeletal myxoid chondrosarcoma
    Subbaya Subramanian
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94035, USA
    J Pathol 206:433-44. 2005
    ..Small molecule inhibitors for PPARG exist and PPARG could be a potential therapeutic target for EMC...
  22. ncbi Keratin-positive Ewing's sarcoma: an ultrastructural study of 12 cases
    Amitabh Srivastava
    Department of Pathology, Tufts New England Medical Center, Boston, MA 02114, USA
    Int J Surg Pathol 13:43-50. 2005
    ..This study shows that keratin-positive EWS/PNETs have evidence of epithelial differentiation ultrastructurally, and may possibly represent a more aggressive subset of the EWS/PNET group of tumors...
  23. ncbi Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognostication
    Mikelle D Bassett
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Cancer 103:409-16. 2005
    ..The authors examined their single institutional experience and correlated their classification with clinical features and outcome...
  24. doi Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma
    Aude Rimella Le Huu
    Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
    Am J Surg Pathol 34:1563-73. 2010
    ..Overall, our results show, for the first time, that Prox1 is an immunohistochemical biomarker helpful in confirming the diagnosis of KHE/TA and in distinguishing it from infantile hemangioma and pyogenic granuloma...
  25. ncbi Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy
    Scott M Schuetze
    Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
    Cancer 103:339-48. 2005
    ..Serial FDG-PET scans were taken to determine the correlation between FDG uptake and patient outcomes in patients receiving multimodality treatment of extremity sarcomas...
  26. ncbi Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans
    Robert B West
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Am J Surg Pathol 28:1063-9. 2004
    ..stanford.edu/tma_portal/apod/). We conclude that Apo D is strongly expressed in DFSPs and neural lesions and may be useful in differentiating DFSP from fibrous histiocytoma...
  27. ncbi Epithelioid sarcoma: the University of Washington experience
    Patrick S Wolf
    University of Washington Medical Center, Seattle, WA 98195, USA
    Am J Surg 196:407-12. 2008
    ..Epithelioid sarcoma is a rare sarcoma with a high local recurrence rate that frequently metastasizes to lymph nodes. We reviewed our experience with adjuvant therapy in patients with this disease...
  28. pmc TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
    B Lawrence
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Pathol 157:377-84. 2000
    ..Notably, a TPM3-ALK oncogene was reported recently in anaplastic lymphoma, and TPM3-ALK is thereby the first known fusion oncogene that transforms, in vivo, both mesenchymal and lymphoid human cell lineages...
  29. pmc Human cancers express a mutator phenotype
    Jason H Bielas
    Department of Pathology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:18238-42. 2006
    ....
  30. ncbi Sox10: a pan-schwannian and melanocytic marker
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Am J Surg Pathol 32:1291-8. 2008
    ..Our results indicate that Sox10 will serve as a more sensitive and specific marker for the diagnosis of melanocytic and schwannian tumors than S100 protein...
  31. ncbi Pathology of soft tissue sarcoma
    Brian P Rubin
    Department of Anatomic Pathology, Lerner Research Institute and Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Natl Compr Canc Netw 5:411-8. 2007
    ....
  32. doi Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    J Cutan Pathol 35:1014-9. 2008
    ..S100 family of proteins consists of over 20 members. We report on S100 subtypes in malignant melanomas (MMs), and BPNSTs and MPNSTs to investigate differential expression...
  33. pmc A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells
    Robert B West
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 103:690-5. 2006
    ....
  34. ncbi Absence of BRAF and NRAS mutations in uveal melanoma
    Frank Cruz
    Oregon Health and Science University OHSU Cancer Institute, Department of Pathology, OHSU and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Cancer Res 63:5761-6. 2003
    ..No NRAS exon 1 mutations were detected in either type of melanoma. We conclude that UMs arise independent of oncogenic BRAF and NRAS mutations, an observation that may have implications for therapies targeted to the NRAS-BRAF pathway...
  35. ncbi FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma
    Cheryl B Vernon
    Department of Radiology Division of Nuclear Medicine, University of Washington, Seattle, Washington, USA
    Skeletal Radiol 32:139-42. 2003
    ..Evaluating the heterogeneity of the tumor at baseline and after response to therapy can provide insight into prognosis and treatment planning...
  36. ncbi Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors
    Samuel Singer
    Department of Pathology and Surgery, Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 20:3898-905. 2002
    ..The aim of this study was to evaluate the prognostic relevance for KIT mutations in a series of GISTs in which the mutations were evaluated intensively by genomic and cDNA sequencing...
  37. ncbi Neonate with a fibrosarcoma and consumptive coagulopathy
    Maryam Asgari
    Division of Dermatology, Department of Pediatrics, University of Washington, 4800 Sand Point Way NE, Seattle, WA 98105, USA
    J Am Acad Dermatol 50:S23-5. 2004
    ..We discuss subtle differences in clinical presentations that might aid in differentiating vascular tumors from fibrosarcomas...
  38. pmc The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status
    Robert B West
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Am J Pathol 165:107-13. 2004
    ..Reactivity for DOG1 may aid in the diagnosis of GISTs, including PDGFRA mutants that fail to express KIT antigen, and lead to appropriate treatment with imatinib mesylate, an inhibitor of the KIT tyrosine kinase...
  39. ncbi Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles
    Subbaya Subramanian
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Oncogene 23:7780-90. 2004
    ..These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated...
  40. pmc Determination of stromal signatures in breast carcinoma
    Robert B West
    Department of Pathology, Stanford University Medical Center, Stanford, California, USA
    PLoS Biol 3:e187. 2005
    ..Our findings suggest that the host stromal response varies significantly among carcinomas and that gene expression patterns characteristic of soft tissue tumors can be used to discover new markers for normal connective tissue cells...
  41. pmc KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?
    Jonathan A Fletcher
    Am J Pathol 161:737-8; author reply 738-9. 2002
  42. doi Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms
    Joshua Weaver
    Pathology and Laboratory Medicine Institute, Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA
    Mod Pathol 21:943-9. 2008
    ....
  43. ncbi Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations
    Michael C Heinrich
    Department of Medicine, Division of Hematology Oncology, Oregon Health Sciences University and Portland VA Medical Center, USA
    Hum Pathol 33:484-95. 2002
    ..These cytogenetic aberrations are undoubtedly important in GIST pathogenesis, but currently they do not play a key role as diagnostic adjuncts...
  44. doi Pleomorphic angiomatoid fibrous histiocytoma: a case confirmed by fluorescence in situ hybridization analysis for EWSR1 rearrangement
    Ilan Weinreb
    Department of Pathology and Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada
    J Cutan Pathol 35:855-60. 2008
    ..Pleomorphic AFH should be included in the differential diagnosis of atypical mesenchymal tumors of skin and superficial subcutis and molecular testing may prove helpful in this regard...
  45. ncbi Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases
    Andrew L Folpe
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
    Am J Surg Pathol 29:1025-33. 2005
    ....
  46. pmc Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans
    Sabine C Linn
    Departments of Pathology, Genetics, and Biochemistry, and Howard Hughes Medical Institute, Stanford University Medical Center, Stanford, California 94305, USA
    Am J Pathol 163:2383-95. 2003
    ....
  47. ncbi Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature
    Andrew L Folpe
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
    Am J Surg Pathol 28:1-30. 2004
    ..Recognition of PMTMCT is critical, as complete resection cures intractable OO. Immunohistochemistry and RT-PCR for FGF-23 confirm the role of this protein in PMTMCT-associated OO...
  48. ncbi TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies
    Jefferson Terry
    Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Am J Surg Pathol 31:240-6. 2007
    ..Our findings establish TLE as a robust immunohistochemical marker for synovial sarcoma, and may have implications for understanding the biology of synovial sarcoma and for developing experimental therapies for this cancer...
  49. ncbi Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions
    Brian P Rubin
    Departments of Anatomic Pathology and Molecular Genetics, Taussig Cancer Center and Lerner Research Institute, The Cleveland Clinic L25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Skeletal Radiol 36:267-8. 2007
  50. pmc Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma
    David M Thomas
    Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine, and Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Center, Victoria, Melbourne, Australia
    J Cell Biol 167:925-34. 2004
    ..Physiologic coupling of osteoblast differentiation to cell cycle withdrawal is mediated through runx2 and p27KIP1, and these processes are disrupted in osteosarcoma...
  51. ncbi Intercellular junctions in Ewing sarcoma/primitive neuroectodermal tumor: additional evidence of epithelial differentiation
    Audrey N Schuetz
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
    Mod Pathol 18:1403-10. 2005
    ..Desmosomal and adherens junction protein expression was rare to absent. Our findings provide additional evidence that ES/PNET frequently show partial epithelial differentiation...
  52. pmc Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1
    Douglas R Stewart
    J Med Genet 44:e61. 2007
    ..Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours that commonly harbour oncogenic mutations in KIT or PDGFRA and are thought to arise from the interstitial cells of Cajal (ICC; the pacemaker cells of the gut)...